Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Disease-modifying antirheumatic drug Stories

2008-11-03 09:00:06

ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were...

2008-10-27 18:00:10

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment. This study showed that ORENCIA(R) (abatacept) in combination with MTX had significantly more patients achieve a Disease Activity Score 28 using C-reactive protein (DAS28 (CRP))-defined remission, compared with MTX plus placebo (PBO) (41.4 percent versus 23.3...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel...

2008-10-10 09:00:52

Biogen Idec, a US-based pharmaceutical company, has announced that its Phase II trial of baminercept in rheumatoid arthritis patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug did not meet its primary endpoint. The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in rheumatoid arthritis (RA), compared to placebo at 14 weeks....

2008-10-09 18:00:37

Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LT(beta)R-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint. The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in RA, compared to placebo at 14 weeks. The study...

2008-09-18 12:00:11

NUTLEY, N.J., Sept. 18 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the Biologics License Application (BLA) for ACTEMRA(R) (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The FDA has not requested any new clinical studies surrounding the efficacy or safety of...

2008-08-19 09:00:16

Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced that it has acquired an oral, once-daily candidate for the treatment of rheumatoid arthritis (RA) which has completed a 160 patient, multi-center, double-blind, randomized, placebo-controlled Phase II clinical trial for the treatment of rheumatoid arthritis (RA). Rheumatoid arthritis is...

2008-08-06 09:00:11

Hollis-Eden Pharmaceuticals has started a Phase I/II open label dose ranging clinical trial with its investigational oral drug candidate Triolex in patients diagnosed with rheumatoid arthritis and receiving a stable dose of methotrexate, the current standard of care in rheumatoid arthritis. The purpose of the Phase I/II clinical trial is to evaluate the safety and tolerance of Triolex when administered orally for 28 days at three different dose levels. The study will also evaluate the...

2008-07-31 12:00:22

Roche has announced that the arthritis advisory committee of the FDA has recommended approval of Actemra, a novel interleukin-6 receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis. The committee's vote was made after Roche presented results from five Phase III clinical trials. The clinical development program was designed to evaluate the effects of Actemra on signs and symptoms of rheumatoid arthritis (RA),...

2008-07-29 15:00:28

NUTLEY, N.J., July 29 /PRNewswire/ -- Roche today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA). "The committee's overwhelmingly positive recommendation brings ACTEMRA one step closer to becoming...